Study Debunks Trump Claim on Paracetamol and Autism Link
A comprehensive review of evidence has definitively rejected US President Donald Trump's assertion that taking paracetamol during pregnancy increases the risk of autism, ADHD, or intellectual disabilities in children. The gold-standard study, published in The Lancet Obstetrics, Gynaecology and Women's Health, analyzed data from 43 previous studies and found no link between maternal paracetamol use and neurodevelopmental issues.
The findings are a stark rebuke to Trump's remarks last September, which sparked widespread anxiety among pregnant women. At the time, he claimed that paracetamol was too hazardous for expectant mothers and advised doctors to advise them against using it. However, the study conclusively debunks these claims, stating that "there is no evidence whatsoever to link the use of paracetamol by pregnant women to autism, ADHD or disabilities in their children."
The researchers behind the study emphasize that familial and genetic factors are more plausible explanations for observed associations between paracetamol use and neurodevelopmental outcomes. Furthermore, they suggest that the underlying health condition prompting regular paracetamol use may play a more significant role in shaping a child's neurodevelopmental status than the medication itself.
Health experts have welcomed the study's findings, urging expectant mothers to disregard any misinformation about paracetamol's safety during pregnancy. "Expectant mothers do not need the stress of questioning whether medicine most commonly used for a headache could have far-reaching effects on their child's health," said Grainne McAlonan, a professor at King's College London.
The study's lead author, Professor Asma Khalil, stressed that paracetamol remains a safe option during pregnancy when taken as guided. "This is important because paracetamol is the first-line medication we recommend for pregnant women in pain or with a fever," she said. "They should feel reassured that they still have a safe option to relieve them of their symptoms."
The study's release has been hailed as a significant victory for public health, ensuring that pregnant women are not subjected to unnecessary anxiety and misinformation about the safety of paracetamol during pregnancy.
A comprehensive review of evidence has definitively rejected US President Donald Trump's assertion that taking paracetamol during pregnancy increases the risk of autism, ADHD, or intellectual disabilities in children. The gold-standard study, published in The Lancet Obstetrics, Gynaecology and Women's Health, analyzed data from 43 previous studies and found no link between maternal paracetamol use and neurodevelopmental issues.
The findings are a stark rebuke to Trump's remarks last September, which sparked widespread anxiety among pregnant women. At the time, he claimed that paracetamol was too hazardous for expectant mothers and advised doctors to advise them against using it. However, the study conclusively debunks these claims, stating that "there is no evidence whatsoever to link the use of paracetamol by pregnant women to autism, ADHD or disabilities in their children."
The researchers behind the study emphasize that familial and genetic factors are more plausible explanations for observed associations between paracetamol use and neurodevelopmental outcomes. Furthermore, they suggest that the underlying health condition prompting regular paracetamol use may play a more significant role in shaping a child's neurodevelopmental status than the medication itself.
Health experts have welcomed the study's findings, urging expectant mothers to disregard any misinformation about paracetamol's safety during pregnancy. "Expectant mothers do not need the stress of questioning whether medicine most commonly used for a headache could have far-reaching effects on their child's health," said Grainne McAlonan, a professor at King's College London.
The study's lead author, Professor Asma Khalil, stressed that paracetamol remains a safe option during pregnancy when taken as guided. "This is important because paracetamol is the first-line medication we recommend for pregnant women in pain or with a fever," she said. "They should feel reassured that they still have a safe option to relieve them of their symptoms."
The study's release has been hailed as a significant victory for public health, ensuring that pregnant women are not subjected to unnecessary anxiety and misinformation about the safety of paracetamol during pregnancy.